Catalent (CTLT)
(Delayed Data from NYSE)
$56.39 USD
+0.18 (0.32%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $56.38 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Brokerage Reports
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 201 - 216 ( 216 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Acquisition Increases Biologics Exposure at a Reasonable Price
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Morning Call
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Downgrade to SW Big Shift in Investor Sentiment Y/Y Reflected in Valuation.
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
While Not Imminent, Taking into Account Industry M-A in Its Valuation
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
While Not Imminent, Taking into Account Industry M-A in Its Valuation.
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Raise PT to $35; Biologics May Emerge as an Investable Theme Moving Forward
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Even When Results Are Good, Focus on the Year, Not the Quarter
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Biopharma Services: PTHN and CTLT Could Take an Extended Look If AMRI Is Looking to Sell
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Raise Price Target to $31; Solid Execution Increases Confidence in Back Half Weighted Guidance
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Medical Technology: 4Q Preview; No Real Changes to Outlooks; Reducing Estimates Again for FX
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Sciences Tools - Services,CDMO Consolidation Trend Ongoing.
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Good Example of the LT Opportunity to Consolidate Fragmented Landscape
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
1Q Execution Another Modest Step Toward Improved Investor Sentiment
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Expecting Investor Sentiment to Improve Through FY17; Initiate OW - $29 PT
Provider: KEYBANC CAPITAL MARKETS